Journal Scans
Multicenter Analysis of 80 Solid Organ Transplantation Recipients With Post-Transplantation Lymphoproliferative Disease: Outcomes and Prognostic Factors in the Modern Era
Rituximab for Post-transplantation Lymphoproliferative Disorder
AM Evens, KA David, I Helenowski, B Nelson, D Kaufman, SM Kircher, A Gimelfarb, E Hattersley, LA Mauro, B Jovanovic, A Chadburn, P Stiff, JN Winter, J Mehta, K Van Besien, S Gregory, LI Gordon, JM Shammo, SE Smith, SM Smith
20100019
2010 Jan 19
J Clin Oncol
Multicenter Analysis of 80 Solid Organ Transplantation Recipients With Post-Transplantation Lymphoproliferative Disease: Outcomes and Prognostic Factors in the Modern Era
J Clin Oncol. 2010 Jan 19;[Epub Ahead of Print], AM Evens, KA David, I Helenowski, B Nelson, D Kaufman, SM Kircher, A Gimelfarb, E Hattersley, LA Mauro, B Jovanovic, A Chadburn, P Stiff, JN Winter, J Mehta, K Van Besien, S Gregory, LI Gordon, JM Shammo, SE Smith, SM Smith
TAKE-HOME MESSAGE
Abstract
SUMMARY
OncologySTAT Editorial Team
Survival rates remain poor for patients who develop post-transplantation lymphoproliferative disorder (PTLD) after solid organ transplantation (SOT). Traditional treatment of PTLD yields responses of <50%, and durable remissions are rare. When rituximab is added to cyclophosphamide, doxorubicin, vincristine, and prednisone in the treatment of patients with immunocompetent diffuse large B-cell lymphoma, long-term survival rates of 60% to 65% have been reported. It is not clear whether rituximab could...
